Characteristic | Asymptomatic patients with DM (n = 63) | Healthy volunteers (n = 7) | p |
---|---|---|---|
Age (years) | 66.3±4.4 | 60.4±4.1 | 0.005* |
Male | 77.8% | 42.8% | 0.07 |
Body mass index (kg/m2) | 25.8±3.9 | 21.1±2.6 | 0.003* |
DM duration (years) | 15.8±8.8 | – | – |
HbA1c (%) | 7.2±1.0 | – | – |
Cardiovascular risk factors | |||
 Systolic blood pressure (mmHg) | 138.1±9.0 | 133.3±5.3 | 0.14 |
 Smoking | 11.1% | 0% | 0.46 |
 High density lipoprotein (mmol/L) | 1.30±0.46 | 1.53±0.43 | 0.10 |
 Total cholesterol (mmol/L) | 4.10±0.71 | 5.26±0.40 | < 0.001* |
Diabetic complications | |||
 eGFR (ml/min/1.73 m2) | 76.6±18.6 | 87.9±10.6 | 0.04 |
 Microalbumin/creatnine ratio (mg/mmol) | 7.89±9.11 | – | – |
 Retinopathy | 14% | – | – |
 Peripheral vascular disease | 1.4% | – | – |
Anti-hypertensives | |||
 Beta-blockers | 17.5% | 0% | 0.59 |
 ACE inhibitor | 46.0% | 0% | 0.04 |
 Calcium channel blockers | 65.1% | 0% | < 0.01* |
 Alpha-blockers | 7.9% | 0% | 1.00 |
 Diuretics | 7.9% | 0% | 1.00 |
 Angiotensin receptor blocker | 19.0% | 0% | 0.34 |
Lipid-modifying agents | |||
 Statin | 61.9% | 0% | < 0.01* |
 Fibrates | 1.6% | 0% | 1.00 |
Anti-hyperglycaemic agents | |||
 Acarbose | 1.6% | 0% | 1.00 |
 Sulfonylureas | 36.5% | 0% | 0.09 |
 SGLT2 inhibitor | 17.5% | 0% | 0.59 |
 Metformin | 90.5% | 0% | < 0.01* |
 DDP-4 inhibitor | 41.3% | 0% | 0.04 |
 Insulin | 30.2% | 0% | 0.18 |
 Pioglitazone | 22.2% | 0% | 0.33 |
Anti-platelet agents | |||
 Clopidogrel | 6.3% | 0% | 1.00 |
 Aspirin | 23.8% | 0% | 0.33 |